1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Legislation

3 Big Medtech Takeaways From US Midterms

 
• By David Filmore

The balance of power will be shifting in Washington, DC, following the Nov. 6 US midterm elections, but that probably will not mean major changes for medtech policies. Here are some key takeaways from the election for device and diagnostics companies.

Vote American Pencil_1200x675

The change in party control in the US House of Representatives from Republican to Democrat following this week's midterm elections will be significant in bringing more oversight of the Trump administration generally, but it's not clear the election will have major specific impacts on the device industry in the near term. Here are three medtech takeaways from the closely watched election:

One thing is clear: the new Democratic leadership of the House will put significant energy into subpoenaing Trump administration officials and conducting hearings and investigations. The focus of the oversight...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legislation

More from Policy & Regulation

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.

Plans For Specific EU Orphan And Pediatric Device Expert Panel Need To Go Further

 
• By Amanda Maxwell

Moves are at last underway for a more specific focus on orphan and pediatric devices. They are a start; but experts are calling for more to support this sector.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 
• By Natasha Barrow

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.